

Supplemental Table I.

Baseline characteristics among White and Black subjects with follow-up

	White (n=474)	Black (n=144)	P-Value
Age, years	68.1 (12.9)	58.8 (11.7)	<0.001
Male	309 (65.2)	73 (50.7)	0.002
Body Mass Index kg/m ²	28.7 (6)	30.6 (7.6)	0.01
Smoking	309 (65.2)	91 (63.2)	0.66
Diabetes	163 (34.4)	73 (50.7)	<0.001
Hypertension	420 (88.6)	131 (91.0)	0.42
Hypercholesterolemia	346 (73.0)	95 (66.0)	0.10
Estimated GFR mL/min/1.73 m ²	68.9 (22.8)	65.7 (39.2)	0.92
History of coronary artery disease	434 (91.6)	128 (88.9)	0.33
History of myocardial infarction	92 (19.4)	28 (19.4)	1.00
History of PCI	223 (47.1)	52 (36.1)	0.02
History of CABG	125 (26.4)	22 (15.3)	0.006
History of heart failure	140 (29.5)	54 (37.5)	0.07
Ejection fraction %	54.8 (11.7)	51.6 (14.5)	0.07
ACE/ARB use	228 (48.1)	71 (49.3)	0.80
Aspirin use	362 (76.4)	111 (77.1)	0.86
Clopidogrel use	179 (37.8)	42 (29.2)	0.06
Statin use	316 (66.7)	91 (63.2)	0.44
Beta blocker use	331 (69.8)	106 (73.6)	0.38

*Data presented as n (%) and mean ± SD.**GFR=Glomerular filtration rate**PCI=Percutaneous coronary intervention**CABG=Coronary artery bypass surgery**ACE/ARB=Angiotensin converting enzyme inhibitors/Angiotensin receptor blockers*

Our initial gate isolated the mononuclear cells (MNC's) as the primary population of interest and from there we drilled down into two gating strategies:

- 1 - MNC/CD34/CD45 med/Quadrant gates - Quadrant gates for VEGF, CD133, and CXCR4
- 2- MNC/CD45-/CD34+++/Quadrant gates - Quadrant gates for VEGF, CD133, and CXCR4